BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...A third program, cusatuzumab, is a first-in-class CD70...
...granted J&J exclusive, worldwide rights to the anti-CD70...
...2C3 – Complement 3C5 – Complement 5CD70 (CD27L)FCRN...
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

...rights to specified Allogene candidates targeting BCMA, CD70...
...Tumor necrosis factor receptor superfamily member 17CD19CD70 (CD27L)DLL3...
BioCentury | Dec 22, 2020
Targets & Mechanisms

Tissue-targeting autoantibodies as a driver of long COVID

One implication of the recent Yale study linking autoantibody production to the development of long COVID is that treatment with therapies directed at B cells or antibody clearance might prove useful in...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...rights to specified Allogene candidates targeting BCMA, CD70...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...other CRISPR-edited allogeneic CAR T programs in the clinic: BCMA-targeting CTX120 for multiple myeloma and CD70-targeting...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...abated following the June readout.J&J is partnered separately with argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) to develop CD70-targeting...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...company is planning to submit an IND for its third TRuC T cell therapy targeting CD70...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...I study of 12 AML patients with a median age of 75, monotherapy with the anti-CD70...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...programs are based on the biotech’s TriMix technology, which combines therapeutic mRNA molecules that encode CD70...
...and financial terms were still being finalized. Targets CD40L (CD40LG; CD154) - CD40 ligand CD70 (CD27L...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
Items per page:
1 - 10 of 98